Research Spending Continues on an Upward Trajectory

Research spending continues on an upward trajectory For the second year in a row, chemical companies ratcheted up investments devoted to novel products and process experimentation L ast year was another good one for chemical firms' corporate research budgets. Spending levels rose, and at a faster rate than they did in 2017. A strong global economy in 2017 encouraged managers to spend more liberally on research in 2018. At least for the first half of the year, economic activity-along with demand for chemicals-hummed along. Only toward the middle of 2018 did threats to global tradeappear. The US and China imposed a series of tit-for-tat tariffs on each other. The pending British exit from the European Union, known as Brexit, sent a shudder up the European business community's spine as it contemplated duties and customs slowdowns.

Chemify and Prepaire Labs announced to expand their partnership with an additional program to tackle the ongoing Opioid crisis and develop a novel class of digitally discovered non-addictive Opioids as pain modulators, as well as drugs tackling Opioid addiction directly by combining Chemify's breakthrough programmable chemistry platform with Prepaire's integrated novel open collaboration drug discovery platform. The project, named Toxifree, comes in response to the FDA's Center for Drug Evaluation and Research (CDER) requesting drugmakers and researchers to develop treatments for stimulant use disorder, hoping to address a major gap in the addiction crisis response.After a successful initial partnership, Chemify and Prepaire are now aiming to leverage Chemify's Chemputation technology which enables the automated and integrated design, discovery, and synthesis of complex molecules on demand using a chemical programming language and Prepaire's advanced open-architecture drug development platform.Under the terms of this partnership, Chemify will design and discover novel compounds to identify Opioid-derived hits and develop them further into candidates. Chemify will receive at least USD $30 million in payments and pre-negotiated, success-driven clinical and regulatory milestones for each developed molecule, as well as single digit royalties on any resulting products.Lee Cronin, Chemify's Founder and CEO and Regius Professor of Chemistry at the University of Glasgow has extensive experience leading research efforts to develop solutions for the opioid crisis. Cronin lead a team that won several NIH-prize challenges including winning the grand runner up prize for the design, discovery and automated synthesis of next generation, safer and non-addictive drug-candidates to help address the opioid crisis."We are extremely excited to combine Chemify's technology for molecular design, discovery and synthesis with the integrated Prepaire platform to expand our collaboration and create a fully integrated, digitally driven drug discovery approach. With this partnership we are breaking ground on a new pain modulation discovery program that aims to tackle the global need for better and non-addictive pain medication. With our unique design approach guided by Chemputation, we are utilizing an evolutionary approach to discovering novel compounds to solve this devastating and critical healthcare need," said Professor Lee Cronin, Chemify's Founder and CEO."Our partnership with Chemify allows our discovery platform to integrate directly with Chemify's chemical space exploration approach, enabling us to access novel chemical matter that would have otherwise been inaccessible. As we progress our collaboration, we are aiming to build an integrated approach that can be used for many more indications beyond novel pain modulators. There aren't any approved treatments to help address addiction to opioids, whose use has surged in recent years. The purpose of this FDA guidance is to assist in the clinical trial designs for the development of novel drugs to support indications for treatment of moderate to severe cocaine use disorder, treatment of moderate to severe methamphetamine use disorder, or treatment of moderate to severe prescription stimulant use disorder," said Dr Vicent Ribas, Prepaire's Co-Founder.About ChemputationDigital chemistry applies principles of computation to chemistry for programable chemistry and Chemify has developed the underpinning infrastructure to make this possible for chemical discovery and synthesis. Like a computer program, digital chemistry programs can automatically run chemical experiments, make new molecules, and ensure that complex chemical recipes are always accessible and perfectly reproducible. Chemical programs are precise pieces of code that allow fully transparent and reliable operation allowing the implementation of AI and other techniques with full audit and safety.About ChemifyBased in Glasgow, Chemify is a pioneering company digitizing chemistry to provide world-leading pharmaceutical, biotechnology, and industrial partners access to an exponentially growing space of novel molecules and materials. By leveraging decades of chemistry experience, hardware robotics, and artificial intelligence, Chemify's Chemputation technology enables companies to access an end-to-end workflow for drug discovery, molecule synthesis, and materials discovery. Chemify was founded by CEO Lee Cronin based on conceptual advancements from Cronin's Digital Chemistry Laboratory at the University of Glasgow in Scotland. By building the infrastructure to digitize chemistry, Chemify is reimagining chemical research, discovery and manufacturing to benefit all of humanity by accelerating advances across chemistry with a focus on medicine and functional materials.About Prepaire LabsPrepaire Labs is a pioneering healthcare technology company focused on revolutionizing drug discovery and precision medicine. Through the integration of deep learning and biology, Prepaire Labs builds predictive models grounded in genetic, phenotypic, and clinical data. These models form a view to the underlying architecture and biology of diseases. Prepaire Labs utilizes patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models that optimize genetics, cell-type, environment, and multidimensional data collection for increased predictability of human clinical outcomes. A state-of-the-art BSL3 lab is opening in May 2024, located at Masdar City, Abu Dhabi, UAE.

Pall Corporation, a leading provider of filtration, separation and purification solutions, introduces SepraLYTE liquid/gas coalescers, an innovative solution designed to meet the increasing demand for efficient separation of electrolyte aerosols from gas in green hydrogen production processes.Leveraging advanced separation technology, SepraLYTE coalescers excel in the separation of water or electrolyte aerosols (30% potassium hydroxide solution) from hydrogen, ensuring the purity of hydrogen produced from electrolysis processes. They are highly suitable for a wide range of separation applications where minimal pressure drop is crucial for downstream processes."Our new SepraLYTE coalescers represent Pall's commitment to serving our customers in energy transition markets. Pall continues to innovate to address new and challenging customer needs in fast growing markets like green hydrogen," said Greg Sears, Vice President and General Manager of Pall's Fluid Technologies and Asset Protection business unit."Pall's coalescers enable our customers to optimize their plant design, maximize the lifetime of their critical equipment and improve overall efficiency, reliability and output," said Sears.These coalescers feature Pall's proprietary melt blown media technology, which achieves outstanding liquid mist separation with low differential pressure. The compact design incorporates coalescer media that ensures compatibility with various chemical applications. Other key advantages of SepraLYTE liquid/gas coalescers is the ease of maintenance, compact size and waste reduction.Utilizing SepraLYTE liquid/gas coalescers, customers gain significant advantages over conventional separation products. These advantages include reliable, consistent and verifiable separation performance, high gas flow and liquid removal in a compact cartridge, which allow for smaller systems with low capital, operating, and maintenance costs.About Pall CorporationPall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of industries. Pall collaborates with customers to advance health, safety, and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste.

LyondellBasell and MSI Technology, LLC announced they have entered into an agreement for MSI Technology to serve the LyondellBasell Polybutene-1 (PB-1) resin line into consumer packaging applications for North America. MSI Technology is also the sales representative for the LyondellBasell Plexar product line. The expansion of the relationship is a strategic fit relative to the markets MSI Technology serves today. MSI Technology will use its technical sales approach combined with its current specialty product portfolio to enhance offerings to customers in consumer packaging.LyondellBasell PB-1 resins are commonly used in consumer packaging applications for easy-open packaging and film modification for seal initiation temperature providingBroad seal-peel temperature rangeConsistent and reproducible peel performanceAdjustable peel force to end-use requirementsSimilar initiation and propagation peel force"Whitening" with "Smooth & Clean" peel surfaceGood seal integrityEasy processabilityUsable in blown film, cast film . click apply for full job details